Michael D. Frost
Co-authored both landmark trials proving an mTOR inhibitor shrinks tuberous sclerosis tumors in the brain and kidney
MD, Saint Louis University (1975) · child neurology fellowship, Univ. of Colorado (1977–1980) · pediatric neurologist/epileptologist, Minnesota Epilepsy Group, St. Paul, MN
Portrait: Minnesota Epilepsy Group
Sat on both pivotal EXIST trials: EXIST-1 (FRA2013) — everolimus shrank SEGA brain tumors ≥50% in 35% vs 0% placebo; EXIST-2 (BIS2013) — everolimus shrank kidney angiomyolipomas ≥50% in 42% vs 0% placebo.
Practices pediatric neurology/epilepsy at Minnesota Epilepsy Group; co-author of the 2021 International TSC Consensus Group diagnostic criteria update.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2013 | H | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial BIS2013 Site investigator on EXIST-2: everolimus shrinks kidney angiomyolipomas ≥50% in 42% vs 0% placebo. |
| 2013 | H | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial FRA2013 Site investigator on EXIST-1: everolimus shrinks SEGA brain tumors ≥50% in 35% vs 0% placebo. |